{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:49:20Z","timestamp":1789044560497,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study evaluated the efficacy and safety of adjunctive clobazam (CLB) in Chinese patients with drug-resistant epilepsy (DRE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively included 121 DRE patients receiving adjunctive CLB at the Epilepsy Center of the Seventh Affiliated Hospital of Sun Yat-sen University (Jan 2023-May 2025). Patients were followed at 1, 3, 6, 9, and 12\u202fmonths or longer. Data collected included epilepsy etiology, seizure type, frequency, treatment duration, dosage, and adverse events. Response was defined as \u226550% reduction in seizure frequency from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 121 patients were included (age at medication use 32.4\u202f\u00b1\u202f13.5\u202fyears; mean three prior failed antiseizure medications; mean follow-up 12\u202fmonths). Seizure types were focal (18.2%), generalized (7.4%), and both (74.4%). At first follow-up, 51.2% achieved \u226550% seizure reduction and 39.7% were seizure freedom; at last follow-up, 85.9% responded and 51.6% were seizure freedom. Response rates increased over time (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Adults had higher response (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.046) and seizure freedom rates (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.041) than children. Concomitant oxcarbazepine (OXC) was associated with increased seizure freedom (\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.03), whereas valproate (VPA) was associated with low response rate (\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.013) but not with seizure freedom. Age at medication (OR\u202f=\u202f1.032,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.035), CLB dosage (OR\u202f=\u202f1.093,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004), and OXC co-therapy (OR\u202f=\u202f2.311,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.04) were independent predictors of seizure freedom. Most common adverse events were somnolence\/mental fatigue (9.9%) and hypersomnia (5%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjunctive CLB significantly reduced seizures in DRE with sustained efficacy. Higher dosage, longer treatment duration, and concomitant OXC use were associated with improved outcomes. CLB showed favorable efficacy, wide applicability, and acceptable safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1757055","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:18:57Z","timestamp":1774502337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of adjunctive clobazam in Chinese patients with drug-resistant epilepsy: a single-center real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yaqian","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]},{"name":"Department of Neurology, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfang","family":"She","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuda","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liemin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the Ilae Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the Ilae commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/j.1528-1157.1986.tb05730.x","article-title":"Current status of the 1,4 and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam","volume":"27","author":"Robertson","year":"1986","journal-title":"Epilepsia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","article-title":"Gaba(a) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam","volume":"26","author":"Sankar","year":"2012","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1756285614521314","article-title":"Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome","volume":"7","author":"Purcarin","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/epi.12561","article-title":"Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years","volume":"55","author":"Conry","year":"2014","journal-title":"Epilepsia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A practical guide to the treatment of Dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"110183","DOI":"10.1016\/j.yebeh.2024.110183","article-title":"Evaluating the patient needs and tolerability of Clobazam liquid formulation (Likozam\u00ae 1 mg\/mL): a French patient and care-givers' centered survey","volume":"163","author":"Scorrano","year":"2025","journal-title":"Epilepsy Behav"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"108671","DOI":"10.1016\/j.yebeh.2022.108671","article-title":"Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: an Indian experience","volume":"130","author":"Satishchandra","year":"2022","journal-title":"Epilepsy Behav"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1212\/CPJ.0000000000000992","article-title":"Efficacy and tolerability of Clobazam in adults with drug-refractory epilepsy","volume":"11","author":"Jamil","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/cns.12399","article-title":"Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy","volume":"21","author":"Gauthier","year":"2015","journal-title":"CNS Neurosci Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"Cd004154","DOI":"10.1002\/14651858.CD004154.pub5","article-title":"Clobazam add-on therapy for drug-resistant epilepsy","volume":"10","author":"Bresnahan","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1528-1157.1991.tb04670.x","article-title":"Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. a retrospective study","volume":"32","year":"1991","journal-title":"Epilepsia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1017\/s0317167100030651","article-title":"Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood","volume":"17","author":"Keene","year":"1990","journal-title":"Can J Neurol Sci"},{"key":"ref18","first-page":"209","article-title":"Effect of clobazam as add-on antiepileptic drug in patients with epilepsy","volume":"140","author":"Joshi","year":"2014","journal-title":"Indian J Med Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s10072-023-06765-1","article-title":"Tolerability of clobazam as add-on therapy in patients aged 50 years and older with drug-resistant epilepsy","volume":"44","author":"Nagarajan","year":"2023","journal-title":"Neurol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/dmcn.14539","article-title":"Is clobazam monotherapy effective and safe in people with focal or generalized seizures? A Cochrane review summary with commentary","volume":"62","author":"Gimigliano","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"Cd009258","DOI":"10.1002\/14651858.CD009258.pub3","article-title":"Clobazam monotherapy for focal or generalized seizures","volume":"7","author":"Arya","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":"Clobazam in the treatment of Lennox-Gastaut syndrome","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/wnl.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1111\/j.1528-1157.1995.tb05996.x","article-title":"Antiepileptic drug mechanisms of action","volume":"36","author":"Macdonald","year":"1995","journal-title":"Epilepsia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/jcph.603","article-title":"Drug-metabolism mechanism: knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions","volume":"56","author":"Tolbert","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"109156","DOI":"10.1016\/j.yebeh.2023.109156","article-title":"The cenobamate-clobazam interaction evidence of synergy in addition to pharmacokinetic interaction","volume":"142","author":"Osborn","year":"2023","journal-title":"Epilepsy Behav"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e88456","DOI":"10.1371\/journal.pone.0088456","article-title":"Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for \u03b1\u2082 versus \u03b1\u2081-Gaba (a)-receptor complexes","volume":"9","author":"Jensen","year":"2014","journal-title":"PLoS One"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1757055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:19:00Z","timestamp":1774502340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1757055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":28,"alternative-id":["10.3389\/fneur.2026.1757055"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1757055","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1757055"}}